Mohini Mondal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohini Mondal has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Sumel Ashique
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India
7 shared publications - Anas Islam
Faculty of Pharmacy, Integral University, Lucknow, India
6 shared publications - Sadique Hussain
Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India
4 shared publications - Sathvik Belagodu Sridhar
College of Pharmacy, Dubai Medical University, Dubai P.O. Box 20170, United Arab Emirates
4 shared publications - Biplab Debnath
Department of Pharmaceutical Technology Bharat Technology Howrah West Bengal India
3 shared publications - Joy Das
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India
3 shared publications
Latest Publications
- 1 October 2026
- Published by Springer Nature in Toxicology and Environmental Health Sciences
- p. 1-19
Microplastics and gut dysbiosis: links to cancer inflammation
- 1 October 2026
- Published by Springer Nature in Toxicology and Environmental Health Sciences
- p. 1-19
Microplastics and gut dysbiosis: links to cancer inflammation
- 8 September 2026
- Published by Springer Nature in Genome Instability & Disease
- Vol. 7 (4) , 20
Circular RNAs at the crossroads of oxidative stress: novel targets for precision therapeutics
- 8 September 2026
- Published by Springer Nature in Genome Instability & Disease
- Vol. 7 (4) , 20
Circular RNAs at the crossroads of oxidative stress: novel targets for precision therapeutics
- 21 April 2026
- Published by Springer Nature in Inflammopharmacology
- Vol. 34 (5) , 2873-2888
Safety and efficacy of COVID-19 vaccines in pregnant and lactating women: a comprehensive review
Breastfeeding plays a critical role in providing essential nutrients and antibodies that enhance the health of new-borns and infants, supporting their immune systems and overall growth and development. Healthcare professionals, universally recommend breastfeeding for the first six months of an infant’s life, in conjunction with an appropriate complementary diet. However, the COVID-19 pandemic has understandably raised concerns among lactating mothers and pregnant women regarding the risks of infection and vaccine safety. Therefore, it is essential to carefully evaluate the potential dangers of COVID-19 transmission within this vulnerable population especially when considering vaccination for pregnant and breastfeeding women. Encouragingly, the United States Food and Drug Administration has granted approval for the use of two COVID-19 vaccines namely, Pfizer-BioNTech COVID-19 and Moderna COVID-19 to contain the spread of the COVID-19 virus. Both vaccines have been approved for administration in pregnant and breastfeeding women, providing much-needed reassurance to those with concerns about vaccine safety. It is important to recognize that the benefits of vaccination for both the mother and the infant far outweigh the risks associated with COVID-19 infection. Therefore, lactating mothers should view vaccination as a vital measure to protect themselves and their infants from the virus. In addition to elaborating on the successes of safety and effectiveness, this review is unique that it also includes current and newly updated evidence published between 2020 and 2025, comprehensively discussing on several newer vaccine platforms together with recent viral variants. Furthermore, it synthesizes information on the transfer of transplacental and a breast-milk antibody that outlines a clear evidence-gap that may direct further research within pregnant and lactating populations. Graphical abstract The alternative text for this image may have been generated using AI.
- 21 April 2026
- Published by Springer Nature in Inflammopharmacology
- Vol. 34 (5) , 2873-2888
Safety and efficacy of COVID-19 vaccines in pregnant and lactating women: a comprehensive review
Breastfeeding plays a critical role in providing essential nutrients and antibodies that enhance the health of new-borns and infants, supporting their immune systems and overall growth and development. Healthcare professionals, universally recommend breastfeeding for the first six months of an infant’s life, in conjunction with an appropriate complementary diet. However, the COVID-19 pandemic has understandably raised concerns among lactating mothers and pregnant women regarding the risks of infection and vaccine safety. Therefore, it is essential to carefully evaluate the potential dangers of COVID-19 transmission within this vulnerable population especially when considering vaccination for pregnant and breastfeeding women. Encouragingly, the United States Food and Drug Administration has granted approval for the use of two COVID-19 vaccines namely, Pfizer-BioNTech COVID-19 and Moderna COVID-19 to contain the spread of the COVID-19 virus. Both vaccines have been approved for administration in pregnant and breastfeeding women, providing much-needed reassurance to those with concerns about vaccine safety. It is important to recognize that the benefits of vaccination for both the mother and the infant far outweigh the risks associated with COVID-19 infection. Therefore, lactating mothers should view vaccination as a vital measure to protect themselves and their infants from the virus. In addition to elaborating on the successes of safety and effectiveness, this review is unique that it also includes current and newly updated evidence published between 2020 and 2025, comprehensively discussing on several newer vaccine platforms together with recent viral variants. Furthermore, it synthesizes information on the transfer of transplacental and a breast-milk antibody that outlines a clear evidence-gap that may direct further research within pregnant and lactating populations. Graphical abstract The alternative text for this image may have been generated using AI.
- Open Access
- 19 March 2026
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 71, 102973
Emerging cases of Naegleria fowleri infection in India: A brief report (2018–2025)
- 19 March 2026
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 71, 102973
Open AccessEmerging cases of Naegleria fowleri infection in India: A brief report (2018–2025)
- Open Access
- 26 February 2026
- Published by Walter de Gruyter GmbH in Drug Metabolism and Personalized Therapy
- Vol. 41 (2) , 59-83
The molecular landscape of kidney stone disease: pathophysiology to personalized intervention
Urolithiasis is a complex and multifactorial disease with rising global prevalence. Traditional management strategies primarily focus on symptom relief and surgical intervention. However, with advances in genomics, metabolomics, and imaging technologies, precision medicine is reshaping the diagnostic and therapeutic landscape of kidney stone diseases. This review explored the integration of genetic screening, individualized metabolic evaluation, and risk stratification to enable tailored treatment plans. We discuss the current and emerging approaches that align with the principles of precision medicine, including the identification of monogenic and polygenic risk factors, advanced imaging for stone composition, and targeted lifestyle or pharmacological interventions. These developments herald a paradigm shift in urolithiasis care, moving beyond reactive treatment toward proactive, patient-specific management.
- 26 February 2026
- Published by Walter de Gruyter GmbH in Drug Metabolism and Personalized Therapy
- Vol. 41 (2) , 59-83
Open AccessThe molecular landscape of kidney stone disease: pathophysiology to personalized intervention
Urolithiasis is a complex and multifactorial disease with rising global prevalence. Traditional management strategies primarily focus on symptom relief and surgical intervention. However, with advances in genomics, metabolomics, and imaging technologies, precision medicine is reshaping the diagnostic and therapeutic landscape of kidney stone diseases. This review explored the integration of genetic screening, individualized metabolic evaluation, and risk stratification to enable tailored treatment plans. We discuss the current and emerging approaches that align with the principles of precision medicine, including the identification of monogenic and polygenic risk factors, advanced imaging for stone composition, and targeted lifestyle or pharmacological interventions. These developments herald a paradigm shift in urolithiasis care, moving beyond reactive treatment toward proactive, patient-specific management.
- 7 February 2026
- Published by Springer Nature
- p. 1-22
ROS-Mediated Cellular Signaling in Metabolic Disorders
- 7 February 2026
- Published by Springer Nature
- p. 1-22
ROS-Mediated Cellular Signaling in Metabolic Disorders
- 7 January 2026
- Published by Walter de Gruyter GmbH in Zeitschrift für Naturforschung C
- Vol. 81 (11-12) , 703-737
Phytomicronutrients in neurodegeneration: modulating microglial dynamics for neuroprotection
Microglial dysfunction plays a critical role in the pathophysiology of several neurodegenerative diseases, including multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease. Emerging evidence suggests that targeting microglial activation could be a promising therapeutic strategy. This review critically examines recent studies investigating the effects of medicinal plant extracts and their bioactive compounds on microglial function. Relevant data from experimental and preclinical studies were analyzed to assess their neuroprotective and anti-inflammatory potential. Phytochemicals that are found in plants, especially flavonoids, alkaloids, and terpenoids, demonstrate important modulatory effects on microglials. These compounds control microglial polarization, inhibit the release of proinflammatory cytokines, and alleviate oxidative stress, thus, alleviating neuroinflammation and enhancing neuro-restoration. The results suggest that medicine plant extracts have effects on major molecular pathways associated with neuroinflammation, which provide new adjunctive treatment to neurodegenerative diseases. Nevertheless, there are still problems in the translation of these preclinical successes into clinical practice. The limited bioavailability, variability in phytochemical composition, and the absence of standardized formulations are some of the challenges that discourage clinical use. Also, thorough safety assessments should be conducted to achieve therapeutic effectiveness with no adverse effects. The medicinal plants and their bioactive compounds hold potential promise in regulating the dysfunction of microglia and in decreasing neuroinflammation. Future studies are needed to enhance the pharmacokinetic characteristics, to provide consistency in formulations, and to perform stringent clinical studies that would substantiate these findings and allow their use in therapeutic regimens of neuroinflammatory disorders.
- 7 January 2026
- Published by Walter de Gruyter GmbH in Zeitschrift für Naturforschung C
- Vol. 81 (11-12) , 703-737
Phytomicronutrients in neurodegeneration: modulating microglial dynamics for neuroprotection
Microglial dysfunction plays a critical role in the pathophysiology of several neurodegenerative diseases, including multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease. Emerging evidence suggests that targeting microglial activation could be a promising therapeutic strategy. This review critically examines recent studies investigating the effects of medicinal plant extracts and their bioactive compounds on microglial function. Relevant data from experimental and preclinical studies were analyzed to assess their neuroprotective and anti-inflammatory potential. Phytochemicals that are found in plants, especially flavonoids, alkaloids, and terpenoids, demonstrate important modulatory effects on microglials. These compounds control microglial polarization, inhibit the release of proinflammatory cytokines, and alleviate oxidative stress, thus, alleviating neuroinflammation and enhancing neuro-restoration. The results suggest that medicine plant extracts have effects on major molecular pathways associated with neuroinflammation, which provide new adjunctive treatment to neurodegenerative diseases. Nevertheless, there are still problems in the translation of these preclinical successes into clinical practice. The limited bioavailability, variability in phytochemical composition, and the absence of standardized formulations are some of the challenges that discourage clinical use. Also, thorough safety assessments should be conducted to achieve therapeutic effectiveness with no adverse effects. The medicinal plants and their bioactive compounds hold potential promise in regulating the dysfunction of microglia and in decreasing neuroinflammation. Future studies are needed to enhance the pharmacokinetic characteristics, to provide consistency in formulations, and to perform stringent clinical studies that would substantiate these findings and allow their use in therapeutic regimens of neuroinflammatory disorders.
- 3 January 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 690, 126545
Oleosomes as emerging Next-Generation carrier for topical drug delivery
- 3 January 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 690, 126545
Oleosomes as emerging Next-Generation carrier for topical drug delivery
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 728
Targeting mtDNA to Modulate Mitochondrial Dysfunction in Neurodegenerative Diseases
Mitochondrial dysfunction is a common pathological feature of neurodegenerative diseases namely Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease. Although these disorders are primarily driven by disease-specific genetic and proteopathic mechanisms, increasing evidence suggests that secondary mitochondrial DNA (mtDNA) damage and heteroplasmy shifts may exacerbate bioenergetic failure and neuronal vulnerability. Distinguishing primary disease mechanisms from downstream mtDNA alterations is critical to accurately evaluate emerging therapeutic strategies. Recent advances in mtDNA-targeted genome editing have enabled the direct manipulation of mitochondrial genomes. Mitochondrially targeted zinc finger nucleases and TALENs can selectively alter mutant mtDNA to induce heteroplasmy shifts, whereas DddA-derived cytosine base editors allow precise base editing without double-strand breaks. However, each platform has distinct limitations related to the target scope, off-target risk, design complexity, and delivery efficiency. The application of CRISPR/Cas-based systems to mammalian mtDNA remains constrained by the unresolved challenges in guiding RNA import. This review critically examines mitochondrial dysfunction and mutant mtDNA accumulation in neurodegenerative diseases. It also evaluates current and emerging mtDNA-editing techniques, and highlights key translational barriers. We highlighted that mtDNA-targeted interventions can be a promising approach for disease-modifying or adjunctive strategies, rather than curative approaches. Graphical Abstract
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 728
Targeting mtDNA to Modulate Mitochondrial Dysfunction in Neurodegenerative Diseases
Mitochondrial dysfunction is a common pathological feature of neurodegenerative diseases namely Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease. Although these disorders are primarily driven by disease-specific genetic and proteopathic mechanisms, increasing evidence suggests that secondary mitochondrial DNA (mtDNA) damage and heteroplasmy shifts may exacerbate bioenergetic failure and neuronal vulnerability. Distinguishing primary disease mechanisms from downstream mtDNA alterations is critical to accurately evaluate emerging therapeutic strategies. Recent advances in mtDNA-targeted genome editing have enabled the direct manipulation of mitochondrial genomes. Mitochondrially targeted zinc finger nucleases and TALENs can selectively alter mutant mtDNA to induce heteroplasmy shifts, whereas DddA-derived cytosine base editors allow precise base editing without double-strand breaks. However, each platform has distinct limitations related to the target scope, off-target risk, design complexity, and delivery efficiency. The application of CRISPR/Cas-based systems to mammalian mtDNA remains constrained by the unresolved challenges in guiding RNA import. This review critically examines mitochondrial dysfunction and mutant mtDNA accumulation in neurodegenerative diseases. It also evaluates current and emerging mtDNA-editing techniques, and highlights key translational barriers. We highlighted that mtDNA-targeted interventions can be a promising approach for disease-modifying or adjunctive strategies, rather than curative approaches. Graphical Abstract
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 513
Decoding Neuroinflammatory Pathways: The Role of the CXCL12-CXCR4/CXCR7 Axis in ALS-Related Cognitive Impairment
Cognitive impairment (CI) and accelerating neuronal deterioration are hallmarks of amyotrophic lateral sclerosis (ALS). Under these circumstances a crucial molecular mechanism in the pathophysiology of CI has been identified: the CXC chemokine receptor type 7 (CXCR7)/CXC chemokine receptor type 4 (CXCR4)/Cysteine-X-cysteine chemokine ligand 12 (CXCL12) region. Research on ALS shows that the CXCR7/CXCR4/CXCL12 complex plays a role in the degeneration of motor neurons and the resulting cognitive decline. JAK/STAT, PI3K/AKT, MAPK, and other signaling pathways are among the ways the axis controls neuronal inflammation, synaptic remodeling, and neuronal maintenance in each of these scenarios. The CXC motif chemokine ligand 12 (CXCL12) and CXC chemokine receptor type 4 (CXCR4) axis is crucial for the start of the inflammatory mechanism because of their function in mediating the chemotaxis of inflammatory cells. By preventing the migration of inflammatory cells via CXCL12 in the inflammatory area, the response to inflammation can be prevented or reduced. Consequently, the development of CXCR4 antagonists has emerged as a cutting-edge strategy for inflammation treatment. Recent research suggests that managing this relationship could reduce cognitive deficits and offer neuroprotective benefits. According to the current review, the CXCL12/CXCR4/CXCR7 pathway may be a promising target for treating cognitive dysfunction in neurodegenerative disorder. It also emphasizes the need for additional research to completely comprehend its function and identify efficient treatments which may result in improved clinical treatment modalities for these debilitating illnesses. Graphical Abstract
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 513
Decoding Neuroinflammatory Pathways: The Role of the CXCL12-CXCR4/CXCR7 Axis in ALS-Related Cognitive Impairment
Cognitive impairment (CI) and accelerating neuronal deterioration are hallmarks of amyotrophic lateral sclerosis (ALS). Under these circumstances a crucial molecular mechanism in the pathophysiology of CI has been identified: the CXC chemokine receptor type 7 (CXCR7)/CXC chemokine receptor type 4 (CXCR4)/Cysteine-X-cysteine chemokine ligand 12 (CXCL12) region. Research on ALS shows that the CXCR7/CXCR4/CXCL12 complex plays a role in the degeneration of motor neurons and the resulting cognitive decline. JAK/STAT, PI3K/AKT, MAPK, and other signaling pathways are among the ways the axis controls neuronal inflammation, synaptic remodeling, and neuronal maintenance in each of these scenarios. The CXC motif chemokine ligand 12 (CXCL12) and CXC chemokine receptor type 4 (CXCR4) axis is crucial for the start of the inflammatory mechanism because of their function in mediating the chemotaxis of inflammatory cells. By preventing the migration of inflammatory cells via CXCL12 in the inflammatory area, the response to inflammation can be prevented or reduced. Consequently, the development of CXCR4 antagonists has emerged as a cutting-edge strategy for inflammation treatment. Recent research suggests that managing this relationship could reduce cognitive deficits and offer neuroprotective benefits. According to the current review, the CXCL12/CXCR4/CXCR7 pathway may be a promising target for treating cognitive dysfunction in neurodegenerative disorder. It also emphasizes the need for additional research to completely comprehend its function and identify efficient treatments which may result in improved clinical treatment modalities for these debilitating illnesses. Graphical Abstract